CA2858699A1 - Composition for inhibiting after-cataract and method of preparing the same - Google Patents
Composition for inhibiting after-cataract and method of preparing the same Download PDFInfo
- Publication number
- CA2858699A1 CA2858699A1 CA2858699A CA2858699A CA2858699A1 CA 2858699 A1 CA2858699 A1 CA 2858699A1 CA 2858699 A CA2858699 A CA 2858699A CA 2858699 A CA2858699 A CA 2858699A CA 2858699 A1 CA2858699 A1 CA 2858699A1
- Authority
- CA
- Canada
- Prior art keywords
- sulfasalazine
- inhibiting
- cataract
- composition
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 206010036346 Posterior capsule opacification Diseases 0.000 title claims abstract description 94
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 76
- 238000000034 method Methods 0.000 title claims abstract description 33
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims abstract description 96
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims abstract description 95
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims abstract description 95
- 229960001940 sulfasalazine Drugs 0.000 claims abstract description 95
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 58
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 58
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 56
- 239000000843 powder Substances 0.000 claims abstract description 21
- 239000003855 balanced salt solution Substances 0.000 claims description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000006320 pegylation Effects 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002953 phosphate buffered saline Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 210000001542 lens epithelial cell Anatomy 0.000 description 25
- 230000000052 comparative effect Effects 0.000 description 21
- 238000013508 migration Methods 0.000 description 13
- 230000005012 migration Effects 0.000 description 13
- 239000002775 capsule Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000007721 medicinal effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 208000002177 Cataract Diseases 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 101001007419 Homo sapiens Lens epithelial cell protein LEP503 Proteins 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 102000055233 human LENEP Human genes 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- -1 2-pyridinylamino Chemical group 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003816 axenic effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- XCSQXCKDEVRTHN-UHFFFAOYSA-N cyclohexa-1,4-diene-1-carboxylic acid Chemical compound OC(=O)C1=CCC=CC1 XCSQXCKDEVRTHN-UHFFFAOYSA-N 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005638 hydrazono group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 108010042502 laminin A Proteins 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2011-0133103 | 2011-12-12 | ||
| KR1020110133103A KR101379930B1 (ko) | 2011-12-12 | 2011-12-12 | 후발성 백내장 억제용 조성물 및 이의 제조 방법 |
| PCT/KR2012/000205 WO2013089307A1 (ko) | 2011-12-12 | 2012-01-09 | 후발성 백내장 억제용 조성물 및 이의 제조 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2858699A1 true CA2858699A1 (en) | 2013-06-20 |
Family
ID=48612735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2858699A Abandoned CA2858699A1 (en) | 2011-12-12 | 2012-01-09 | Composition for inhibiting after-cataract and method of preparing the same |
Country Status (9)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180255856A1 (en) * | 2017-03-03 | 2018-09-13 | Stormy McCowen TAYLOR | Hair filler device |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101379930B1 (ko) | 2011-12-12 | 2014-04-14 | 가톨릭대학교 산학협력단 | 후발성 백내장 억제용 조성물 및 이의 제조 방법 |
| KR101412776B1 (ko) * | 2013-03-11 | 2014-07-01 | 가톨릭대학교 산학협력단 | 각결막염 치료용 점안제 조성물 및 이의 제조 방법 |
| KR101895950B1 (ko) * | 2015-12-18 | 2018-09-06 | (주)한국비엠아이 | 골관절염 치료를 위한 친수화된 설파살라진 및 히알루론산을 포함하는 조성물 및 이의제조방법 |
| EP3400941B1 (en) * | 2016-01-06 | 2021-03-10 | Keio University | Antitumor agent |
| US10385096B2 (en) * | 2016-08-30 | 2019-08-20 | Council Of Scientific & Industrial Research | Pro-Amb reverse turn restricted bioactive peptide analogues |
| EP3538071B1 (en) | 2016-11-10 | 2022-09-14 | Medisca Pharmaceutique Inc. | Pharmaceutical compounding methods and systems |
| CN116172885A (zh) * | 2021-12-17 | 2023-05-30 | 河南省人民医院 | 一种抗后发性白内障药物制剂及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093487A (en) * | 1986-01-06 | 1992-03-03 | Mobay Corporation | Low viscosity high molecular weight filter sterilizable hyaluronic acid |
| KR100490286B1 (ko) | 2001-09-12 | 2005-05-17 | 주식회사 뉴로테크 | 설파살라진을 활성성분으로 함유하는 것을 특징으로 하는망막손상 치료용 안약 조성물과 그 제조방법 |
| PT1526859E (pt) | 2002-08-07 | 2013-01-25 | Medidom Lab | Processo para preparação de uma formulaçâo de ácido hialurónico de elevado peso molecular |
| KR20030069917A (ko) | 2003-06-27 | 2003-08-27 | 주식회사 뉴로테크 | 안질환 예방 및 치료용 약학적 조성물 |
| US8802651B2 (en) | 2004-06-30 | 2014-08-12 | Abbott Medical Optics Inc. | Hyaluronic acid in the enhancement of lens regeneration |
| KR100894042B1 (ko) * | 2007-04-13 | 2009-04-20 | 가톨릭대학교 산학협력단 | 설파살라진-히알루론산 혼합물의 제조방법 및 이로부터얻어진 혼합물을 포함하는 후발성 백내장 억제용 조성물 |
| CN102106838A (zh) | 2009-12-23 | 2011-06-29 | 上海信谊嘉华药业有限公司 | 一种柳氮磺吡啶肠溶制剂及其制备方法 |
| CN102225220A (zh) | 2011-06-14 | 2011-10-26 | 天津晶明新技术开发有限公司 | 眼科手术粘弹剂 |
| KR101379930B1 (ko) | 2011-12-12 | 2014-04-14 | 가톨릭대학교 산학협력단 | 후발성 백내장 억제용 조성물 및 이의 제조 방법 |
-
2011
- 2011-12-12 KR KR1020110133103A patent/KR101379930B1/ko active Active
-
2012
- 2012-01-09 BR BR112014014038A patent/BR112014014038A2/pt not_active IP Right Cessation
- 2012-01-09 EP EP12858133.7A patent/EP2792356A4/en not_active Withdrawn
- 2012-01-09 WO PCT/KR2012/000205 patent/WO2013089307A1/ko active Application Filing
- 2012-01-09 US US14/364,325 patent/US9364552B2/en not_active Expired - Fee Related
- 2012-01-09 CA CA2858699A patent/CA2858699A1/en not_active Abandoned
- 2012-01-09 JP JP2014547077A patent/JP5843975B2/ja not_active Expired - Fee Related
- 2012-01-09 CN CN201280069538.7A patent/CN104168901A/zh active Pending
- 2012-01-09 IN IN5738DEN2014 patent/IN2014DN05738A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180255856A1 (en) * | 2017-03-03 | 2018-09-13 | Stormy McCowen TAYLOR | Hair filler device |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140378410A1 (en) | 2014-12-25 |
| IN2014DN05738A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-04-10 |
| BR112014014038A2 (pt) | 2017-06-13 |
| KR101379930B1 (ko) | 2014-04-14 |
| KR20130066319A (ko) | 2013-06-20 |
| US9364552B2 (en) | 2016-06-14 |
| EP2792356A4 (en) | 2015-11-11 |
| JP5843975B2 (ja) | 2016-01-13 |
| WO2013089307A1 (ko) | 2013-06-20 |
| JP2015500334A (ja) | 2015-01-05 |
| CN104168901A (zh) | 2014-11-26 |
| EP2792356A1 (en) | 2014-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9364552B2 (en) | Composition for inhibiting after-cataract and method of preparing the same | |
| Graue et al. | The protective effect of Na-hyaluronate to corneal endothelium | |
| EP3452075B1 (en) | Ophthalmic pharmaceutical composition | |
| AU2016396661B2 (en) | Cross-linking agents and associated methods | |
| Dubey et al. | Formulation and evaluation of stimuli-sensitive hydrogels of timolol maleate and brimonidine tartrate for the treatment of glaucoma | |
| CN102652022A (zh) | 治疗干眼综合征的药物组合物 | |
| US11191751B1 (en) | Topical ophthalmological atropine free base compositions | |
| US20190282596A1 (en) | Pharmaceutical composition containing 8 oxo-deoxyguanosine or pharmaceutically acceptable salt thereof as active ingredient for treating corneal disease | |
| CA3201847A1 (en) | Pharmaceutical composition comprising frataxin fusion protein and methods of use thereof | |
| KR20000049136A (ko) | 후발 백내장 억제제 | |
| KR100894042B1 (ko) | 설파살라진-히알루론산 혼합물의 제조방법 및 이로부터얻어진 혼합물을 포함하는 후발성 백내장 억제용 조성물 | |
| KR101507504B1 (ko) | 안구건조증 및 관련 안과 질환의 치료용 점안제 조성물 및 이의 제조 방법 | |
| AU2020103417A4 (en) | Preparation of TN14003 Thermo-sensitive Gel for Treatment of Osteoarthritis by Intraarticular Injection | |
| Shukla | Formulation, Development, and In Vitro, In Vivo, Ex Vivo Characterization of In Situ Gel Containing Blueberry Extract for the Management of Glaucoma | |
| US20210154210A1 (en) | Ophthalmic Formulations and Uses Thereof | |
| TWI887256B (zh) | 供用於預防及/或治療周邊神經病變及其相關疾病的調配物 | |
| US20250134849A1 (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin | |
| Yang et al. | Combinatorial therapeutic drug delivery of riboflavin and olopetadine for the treatment of keratoconus affected corneas of mice | |
| Ka et al. | Formulation and Evaluation of Topically Retained Hydrogels Loaded with Timolol Maleate Microspheres for Extended Release in Treating Glaucoma. | |
| Qin et al. | In Situ Thermoreversible Gel of Tobramycin and Dexamethasone for the Treatment of Keratoconus: Ex-Vivo Permeation and Hemolytic Toxicity | |
| AU2023255001A1 (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin | |
| TW202108144A (zh) | 供用於預防及/或治療周邊神經病變及其相關疾病的調配物 | |
| CN117503691A (zh) | 一种具有减轻老视作用的长效眼用制剂 | |
| HK40003059A (en) | Atropine-containing aqueous composition | |
| Nagare Rupali et al. | International Journal for Pharmaceutical Research Scholars (IJPRS) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140609 |
|
| FZDE | Discontinued |
Effective date: 20180109 |